At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PET Study Examining the Dopaminergic Activity of Armodafinil in Adults
In Brief
A Phase 2 clinical trial evaluating armodafinil for Healthy. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor occupancy of armodafinil using positron emission tomography (PET) scanning with C-11 altropane as the ligand and 2) to document the increased intrasynaptic dopamine produced by armodafinil using PET scanning with C-11 raclopride as the ligand. We hypothesize that DAT occupancy will be low with armodafinil; less than the DAT occupancy produced by therapeutic doses of methylphenidate. We also hypothesize that increases in intrasynaptic dopamine will be relatively low with armodafinil.
Study Details
Timeline
Interventions
tablet, taken by mouth, once each study day